View Single Post
Old 09-20-2021, 02:43 PM   #312
Canada 02
Franchise Player
 
Canada 02's Avatar
 
Join Date: Feb 2004
Exp:
Thumbs up

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older. The antibody responses in the participants given 10 µg doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunized with 30 µg doses. The 10 µg dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age. These are the first results from a pivotal trial of a COVID-19 vaccine in this age group.

https://www.pfizer.com/news/press-re...opline-results

F*** all the anti-vaxxers. Once my kids are safe, I won't give a f*** about this anymore
Canada 02 is offline   Reply With Quote
The Following 6 Users Say Thank You to Canada 02 For This Useful Post: